119-HR-2821 DC Insider Whip Count Analysis

Breakdown: where the votes are likely to land

This is a low‑controversy, implementation bill with demonstrated cross‑party support in both chambers.

• House Energy & Commerce advanced H.R. 2821 on a 44–0 final committee roll call (May 21, 2026), signaling unified support from majority and minority members. [1]U.S. House (docs.house.gov) — E&C Full Committee Roll Call Vote #14 (H.R. 2821)…
• Health Subcommittee forwarded the bill to full committee by voice vote on May 13, 2026, another bipartisan indicator. [2]House Energy & Commerce Committee — Health Subcommittee advances FDA/Medicare b…
• Senate passed the companion S.355 by unanimous consent on December 16, 2025; the measure was received and is held at the House desk, giving leadership a ready vehicle. [3]Congress.gov — All Info – S.355 (FDA Modernization Act 3.0), actions and status
• Given the bipartisan committee record and prior Senate UC, the expected path is House floor under suspension of the rules (two‑thirds required), a procedure commonly used for consensus items. [4]Congressional Research Service (Congress.gov) — CRS: Suspension of the Rules: H…
• No material executive‑branch headwinds: FDA has active workstreams on non‑animal “new approach methodologies” (NAMs) and recently released draft guidance on alternatives, aligning agency practice with the bill’s direction to formalize regulatory updates. [5]U.S. Food & Drug Administration — FDA: New Approach Methodologies (NAMs) overvi…

Key legislators and potential swing considerations

The coalition spans both parties; pivotal roles are procedural, not ideological.

• House floor managers/committee leads: Chair Brett Guthrie (E&C) and Health Subcommittee Chair Morgan Griffith have been front‑footed on the markup schedule; Ranking Member Frank Pallone signaled Democratic buy‑in via participation and statements in the markup record. [6]House Energy & Commerce Committee — E&C: Chairmen Guthrie and Griffith announce…
• House sponsors span both parties and both Carters (GA and LA): Buddy Carter (R‑GA), Nanette Barragán (D‑CA), Vern Buchanan (R‑FL), Rosa DeLauro (D‑CT), Diana Harshbarger (R‑TN), Troy Carter (D‑LA). Expect each to help drive votes and manage stakeholder messaging. [7]U.S. House (docs.house.gov) — H.R. 2821 introduced text (sponsor list)
• Senate champions include Cory Booker (D‑NJ) and Rand Paul (R‑KY), with additional bipartisan co‑sponsors; their UC win lowers any inter‑chamber friction if the House opts to accept the Senate vehicle. [8]booker.senate.gov
• Outside pressure vectors: animal‑welfare/modernization coalition publicly pushing enactment (e.g., ModernizeTesting/Animal Wellness Action), while research‑stakeholder groups emphasize validated use of alternatives (e.g., NABR’s stance on FDAMA 2.0). Net effect is supportive with a cautionary tone on scientific validation—unlikely to produce organized House opposition. [9]Modernize Testing Coalition — ModernizeTesting coalition press page (Senate pas…

Leadership influence and procedural dynamics

Floor timing and vehicle selection are the leverage points.

• House leadership: Speaker Mike Johnson controls floor access; consensus measures typically ride the suspension calendar early‑week. E&C’s unanimous vote strengthens the case for that route. [10]U.S. House of Representatives — House Leadership
• Senate posture: Majority Leader John Thune leads a chamber that has already cleared S.355 by UC; if the House passes H.R. 2821 with identical text, enrollment is straightforward. If not, leaders can resolve via exchange of messages or take up the Senate‑passed bill. [11]U.S. Senate — U.S. Senate leadership & officers (119th Congress)
• Committee jurisdiction: In the Senate, HELP is chaired by Bill Cassidy (R‑LA) for the 119th Congress—relevant context but largely moot given prior UC passage. [12]help.senate.gov
• Agency alignment: FDA’s ongoing NAMs work and fresh draft guidance on non‑animal alternatives reduce implementation risk and undercut arguments for delay. [5]U.S. Food & Drug Administration — FDA: New Approach Methodologies (NAMs) overvi…

Assessment: likelihood of passage

Bottom line from a vote‑count and process perspective.

• Likelihood: High. Committee vote was 44–0; Senate already passed its companion by UC; FDA is procedurally aligned; and the bill’s scope is largely technical/implementing prior law. [1]U.S. House (docs.house.gov) — E&C Full Committee Roll Call Vote #14 (H.R. 2821)…
• Confidence: High, contingent on floor time. The only credible risk is scheduling in a crowded pre‑recess window; suspension still requires two‑thirds, but E&C Democrats’ unified support makes the math workable even with majority absences. [1]U.S. House (docs.house.gov) — E&C Full Committee Roll Call Vote #14 (H.R. 2821)…

• Watch‑fors on the floor:
• - Any last‑minute holds from members citing basic‑science concerns are unlikely to scale given the bill’s limited scope and FDA’s NAMs posture. [5]U.S. Food & Drug Administration — FDA: New Approach Methodologies (NAMs) overvi…
• - If a non‑harmonized House text emerges, expect a short exchange of messages; still low risk given bipartisan Senate posture. [3]Congress.gov — All Info – S.355 (FDA Modernization Act 3.0), actions and status